Last reviewed · How we verify
Hormonal Contraception
Hormonal contraception prevents pregnancy by suppressing ovulation through synthetic hormones that inhibit the luteinizing hormone (LH) surge.
Hormonal contraception prevents pregnancy by suppressing ovulation through synthetic hormones that inhibit the luteinizing hormone (LH) surge. Used for Pregnancy prevention / Contraception.
At a glance
| Generic name | Hormonal Contraception |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | Hormonal contraceptive |
| Target | Estrogen receptor, Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Health / Contraception |
| Phase | Phase 3 |
Mechanism of action
Hormonal contraceptives typically contain estrogen and/or progestin that work together to inhibit the hypothalamic-pituitary-gonadal axis, preventing the LH surge necessary for ovulation. Additionally, these hormones thicken cervical mucus to impede sperm transport and alter the endometrium to reduce implantation likelihood. The specific formulation and hormone ratios determine the contraceptive efficacy and side effect profile.
Approved indications
- Pregnancy prevention / Contraception
Common side effects
- Nausea
- Headache
- Breast tenderness
- Breakthrough bleeding
- Mood changes
- Venous thromboembolism
- Hypertension
Key clinical trials
- The Influence of Combined Oral Contraception on the DEvelopment and progRession of Chronic venoUs diSeases (NA)
- Effect of Different Sex Hormone Profiles for the Response to Physical Training (NA)
- Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease (PHASE4)
- Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age (EARLY_PHASE1)
- Open Label, Dose Escalation, Repeat Dose Study Evaluating YCT-529 in Healthy Males (PHASE1, PHASE2)
- How Estrogen Fluctuations Before Diagnosis Affect the Size Prolactin-secreting Tumors
- Gynaecological Care for Transgender People in France in 2024.
- Alii Supplement Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hormonal Contraception CI brief — competitive landscape report
- Hormonal Contraception updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI